2025
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
Mercier B, Govindarajan A, Castro D, Li X, Philip E, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Chehrazi‐Raffle A, Ebrahimi H, Rock A, Zengin Z, Meza L, Dizman N, Hsu J, Liu S, Dorff T, Pal S, Tripathi A. Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Medicine 2025, 14: e70696. PMID: 40145383, PMCID: PMC11947756, DOI: 10.1002/cam4.70696.Peer-Reviewed Original ResearchConceptsHepatitis B/C infectionHIV infectionClinical trialsConcurrent malignancyBrain metastasesVariant histologyEligibility criteriaPresence of brain metastasesAmerican Society of Clinical OncologyMetastatic urothelial cancerFisher's exact testType of therapyContemporary clinical trialsFriends of Cancer ResearchInclusion of patientsUrothelial cancerExact testClinical OncologyTherapy efficacyCancer clinical trialsCancer trialsHIVPatientsExclusion criteriaInfection
2023
Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential
Hamley M, Leyk S, Casar C, Liebold I, Al Jawazneh A, Lanzloth C, Böttcher M, Haas H, Richardt U, Rothlin C, Jacobs T, Huber S, Adlung L, Pelczar P, Henao‐Mejia J, Bosurgi L. Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential. European Journal Of Immunology 2023, 54: e2350434. PMID: 37971166, DOI: 10.1002/eji.202350434.Peer-Reviewed Original ResearchMucosal healingSchistosoma mansoni infectionCytokines IL-4Innovative therapeutic approachesDifferent intestinal diseasesWound-healing potentialIntestinal damageMucosal responsesMansoni infectionInflamed colonIL-4Intestinal disordersIntestinal diseaseNormal mucosaMurine modelTherapeutic approachesNovel regulatorType 2Advanced stageTherapy efficacyMacrophage responseCell therapyHealing potentialNew targetsIntestinal regenerationA pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial
Malarkey M, Toscano A, Bagheri M, Solomon J, Machado L, LoRusso P, Chen A, Folio L, Goncalves P. A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial. Heliyon 2023, 9: e18680. PMID: 37593628, PMCID: PMC10428039, DOI: 10.1016/j.heliyon.2023.e18680.Peer-Reviewed Original ResearchACC patientsClinical trialsTarget lesionsSolid tumorsPhase II clinical trialPilot studyPhase 2 trialResponse Evaluation CriteriaSalivary gland cancerRare salivary gland cancerSystemic therapy efficacyStable diseaseGland cancerLung lesionsComputed tomography (CT) examsCystic carcinomaTherapy responseBlinded observersTomography examsTherapy efficacyLesionsInter-observer variationPatientsAppropriate evaluationTrialsRespiratory viruses: New frontiers—a Keystone Symposia report
Cable J, Sun J, Cheon I, Vaughan A, Castro I, Stein S, López C, Gostic K, Openshaw P, Ellebedy A, Wack A, Hutchinson E, Thomas M, Langlois R, Lingwood D, Baker S, Folkins M, Foxman E, Ward A, Schwemmle M, Russell A, Chiu C, Ganti K, Subbarao K, Sheahan T, Penaloza‐MacMaster P, Eddens T. Respiratory viruses: New frontiers—a Keystone Symposia report. Annals Of The New York Academy Of Sciences 2023, 1522: 60-73. PMID: 36722473, PMCID: PMC10580159, DOI: 10.1111/nyas.14958.Peer-Reviewed Original ResearchConceptsRespiratory virusesSARS-CoV-2Specific viral strainsMechanisms of diseaseAcute infectionChronic diseasesCommon causeEffective treatmentNovel treatmentsVirus-host interactionsPrevention strategiesTherapy efficacyViral strainsVulnerable populationsPrevention approachesVirusDiseaseSymposium reportTreatmentViral biologyMorbidityPopulationInfectionMortalityInfluenzaEfficacy of Cognitive Behavioral Therapy for Alcohol and Other Drug Use Disorders: Is a One-Size-Fits-All Approach Appropriate?
Magill M, Kiluk B, Ray L. Efficacy of Cognitive Behavioral Therapy for Alcohol and Other Drug Use Disorders: Is a One-Size-Fits-All Approach Appropriate? Substance Abuse And Rehabilitation 2023, 14: 1-11. PMID: 36844999, PMCID: PMC9948631, DOI: 10.2147/sar.s362864.Peer-Reviewed Original ResearchUsual care control conditionCare control conditionDrug use disordersUse disordersEvidence-based treatmentsCognitive behavioral therapyMechanism of actionCBT effectsControl conditionDemonstrated efficacyCBT efficacyForm of CBTBehavioral therapyTherapy efficacyAdult alcoholAOD useMotivational interviewingNarrative overviewContingency managementEfficacyIntervention outcomesTraditional CBTCBTPreliminary evidenceEffect size
2022
Chapter 25 Pharmacogenomics and outcomes for hepatocellular cancer treatment
Ghanta M, Hussain M, Karnalkar A, Nagabhishek S, Nuthalapati P, Bhaskar L. Chapter 25 Pharmacogenomics and outcomes for hepatocellular cancer treatment. 2022, 401-414. DOI: 10.1016/b978-0-323-99283-1.00003-3.Peer-Reviewed Original ResearchHepatocellular carcinomaEffects of systemic treatmentRisk factorsPrevalence of genetic variantsSystemic therapy efficacyHepatocellular carcinoma recurrenceHuman genomeMultiple genesSingle-geneGenetic variantsSystemic treatmentPharmacogenomicsGenetic abnormalitiesTherapy efficacyViral infectionGenetic mutationsEconomic burdenPotential targetGeographic prevalenceEfficacyGenomeFood habitsRiskGenesCarcinoma
2020
A Word of Caution for Future Studies in Patellofemoral Pain: A Systematic Review With Meta-analysis
Grant C, Fick CN, Welsh J, McConnell J, Sheehan FT. A Word of Caution for Future Studies in Patellofemoral Pain: A Systematic Review With Meta-analysis. The American Journal Of Sports Medicine 2020, 49: 538-551. PMID: 32816535, PMCID: PMC9906796, DOI: 10.1177/0363546520926448.Peer-Reviewed Original ResearchConceptsPatellofemoral painPatellofemoral kinematicsSystematic reviewCase-control studyUnderlying mechanismQuality assessment checklistMethodological variabilityWeb of SciencePatient characteristicsCofounding variablesGreater effect sizePatellar maltrackingPrevious traumaPainMaltrackingDiagnostic valueTherapy efficacyLateral maltrackingLiterature searchFull extensionLarge methodological variabilityAssessment checklistClinical communityWord of cautionPrimary aim
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply